S

Solventum

Global healthcare company: wound care, dental

Environmental Health & Safety Manager

Full-TimeUpdated on 10/23/2026
$143.2k - $196.9k
Senior, Expert
Bachelor's, Master's
Monrovia, CA, USA
In PersonOnsite in Monrovia, California; travel may include up to 5% domestic/international.
Facilities OperationsEnvironmental Health & Safety
No H1B Sponsorship

About the job

Requirements
  • A Bachelor's degree or higher and seven years of experience in Environmental Health, Safety, Engineering, and/or Manufacturing, or a high school diploma/GED and eleven years of experience in those fields.
  • Three years of experience in a supervisory role.
  • A Master's degree or higher in Environmental Health and Safety, Engineering, Science, or a related discipline is preferred.
  • Ten years of Environmental Health and Safety experience in a manufacturing or production environment is preferred.
  • Experience leading an EHS function or team with responsibility for risk reduction, regulatory compliance, and EHS program implementation is preferred.
  • Experience developing, implementing, and sustaining EHS programs, policies, and procedures across manufacturing or production operations is preferred.
  • Lean Six Sigma Black Belt, Quality Improvement certification, or equivalent continuous improvement certification is preferred.
  • Experience leading change management initiatives related to EHS programs, regulatory requirements, operational improvements, or organizational transformation is preferred.
  • Experience communicating EHS requirements, compliance obligations, and program objectives to leaders, employees, regulators, and other stakeholders is preferred.
  • Experience with state and federal environmental, health, and safety regulations, including OSHA, EPA, and related regulatory agencies is preferred.
  • A professional EHS certification such as Certified Safety Professional (CSP), Certified Industrial Hygienist (CIH), Certified Hazardous Materials Manager (CHMM), or similar credential is preferred.
  • Must be legally authorized to work in the country of employment without sponsorship for employment visa status, such as H1B status.
Responsibilities
  • Provide environmental, health, and safety leadership and direction in consultation with the leadership team at the Monrovia site and Corporate EHS Team.
  • Set short- and long-term strategic direction, site EHS priorities, and resource assignments.
  • Manage maintenance and improvement of the site's implementation of the Solventum EHS Management System and Facility EHS program plans, including incident investigations, response teams, Management of Change processes, EHS systems, data and methodologies, process safety assurance, industrial hygiene, fire protection, and ergonomics.
  • Manage risk and protect employees, assets, and intellectual property; ensure compliance with applicable standards and regulations and conformance with Solventum EHS expectations.
  • Support and communicate with site management, which is accountable for site EHS performance.
  • Elevate site EHS culture through standard work, employee engagement, mentoring and coaching, effective people and capital resources, and a full-compliance mindset.
  • Align department goals, metrics, and targets with the plant vision and targets.
  • Manage site performance targets and coach and lead salaried and hourly employees.
  • Interact with internal auditors and regulatory agencies and serve as liaison between Solventum and governmental agencies to obtain permits related to health, safety, and the environment for plant operations.
  • Develop and maintain the team's technical competency and provide leadership, coaching, and direction to direct reports.
  • Keep up to date with applicable regulations.
  • Comply with corporate policies, procedures, and security standards while performing assigned duties.

About the company

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Eagan, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9.5%, and management raised EPS guidance to $7.10-$7.20.
  • Solventum announced HIS separation on August 5, 2026, sharpening its MedTech focus.
  • The $200 million Eagan Innovation Hub supports roughly 20 launches over two years.

What critics are saying

  • Management expects HIS separation to cut margins about 400 basis points after offsets.
  • ERP cutover orders distorted Q2 2026; Q3 growth resets when demand normalizes.
  • Legal costs, restructuring, and separation complexity keep Solventum exposed until 2027-2028 transactions close.

What makes Solventum unique

  • Solventum combines MedSurg, Dental, and clinical workflow assets from 3M’s healthcare spinout.
  • Its 2026 Eagan Innovation Hub concentrates wound care, sterilization, and digital health R&D.
  • The company still sells into over 75% of U.S. hospitals through entrenched workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

6%

1 year growth

5%

2 year growth

9%
PR Newswire
Oct 19th, 2026
Solventum wins FDA clearance to combine Restrata Matrix with V.A.C. Therapy for wound healing

Solventum has received US Food and Drug Administration (FDA) 510(k) clearance to use Restrata Synthetic Electrospun Fiber Matrix together with its V.A.C. Therapy, the company announced on October 19, 2026. The clearance follows Solventum's acquisition of Acera Surgical in December 2025. Restrata is a fully synthetic, resorbable matrix that supports soft tissue repair, while V.A.C. Therapy applies negative pressure to promote wound healing. Solventum says the matrix resists enzymatic degradation and matches the dressing's wear time of up to seven days. Many collagen-based dressings degrade too early for such use. The pairing may mean fewer dressing changes and a more predictable workflow for care teams. "We're giving clinicians an effective way to streamline care and support better patient outcomes," said Kelley Moffett, president of Advanced Wound Care at Solventum.

Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.